Significant Revenue Growth
NeuroPace's total revenue grew by 22% in 2024 to $79.9 million, compared to $65.4 million in 2023. This growth was primarily driven by increased sales of the RNS system and Dixie Medical SEEG products.
Record Quarterly Revenue
NeuroPace reported record quarterly revenue in Q4 2024, with revenue of $21.5 million, representing a growth of 19% compared to $18 million in Q4 2023.
Gross Margin Stability
Gross margins for Q4 2024 were 75.4%, showing improvement from 75.2% in Q4 2023, demonstrating effective management of gross and operating margins.
Successful Public Offering
NeuroPace completed a public offering with net proceeds of approximately $69.8 million, which strengthened the balance sheet and supported long-term plans.
Project CARE Progress
The Project CARE program showed positive early trends, contributing to revenue growth in the second half of 2024 with increased implants and referrals.
Advancement in Clinical Trials
Positive three-year safety and effectiveness data from the ongoing post-approval study of the RNS system were announced, indicating unmatched seizure control.
Product Development Initiatives
NeuroPace is developing AI-enabled software tools and a next-generation platform to enhance efficiency and efficacy, including an AI-powered seizure classifier.